Home → Symptoms & Diagnosis → Types of Breast Cancer → Ask-the-Expert Conferences: Types of Breast Cancer → October 2006: Inflammatory Breast Cancer → Possible extended Femara treatment?

Possible extended Femara treatment?

Page last modified on: October 13, 2008

Question from Cathy: I am the minority with IBC that was also HER2, ER and PR positive. I have completed combination chemo, mastectomy, radiation, Herceptin and am now on Femara. Do you think Femara treatment will be extended beyond the 5-year plan?: Answer —Gabriel Hortobagyi, M.D., F.A.C.P.: That's a crystal ball question. I think we could say that there are ongoing clinical trials to determine whether prolonging the duration of Femara or similar drugs beyond 5 years is useful and well tolerated. The results of those trials will become available probably in the next 3-5 years.

On Wednesday, October 18, 2006, our Ask-the-Expert Online Conference was called Inflammatory Breast Cancer. Gabriel Hortobagyi, M.D., Thomas Buchholz, M.D., and moderator Jennifer Sabol, M.D. answered your questions about inflammatory breast cancer, a rare but aggressive form of breast cancer.

The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.

Email Updates

Stay informed about current research, online events, and more.

Visit our Gift Shop!

Shop Now »

Meet the Experts

Gabriel N. Hortobagyi, M.D., F.A.C.P. chairs the department of breast medical oncology and directs the Breast Cancer Research Program at the University of Texas M.D. Anderson Cancer Center, where he also serves as professor of medicine and holds the Nellie B. Connally Chair in Breast Cancer.

Thomas A. Buchholz, M.D. is professor of radiation oncology at The University of Texas M.D. Anderson Cancer Center. Dr. Buchholz' research includes the role of radiation treatment in preventing breast cancer recurrence and whether certain genes may be able to predict how breast cancer responds to treatment.

Jennifer Sabol, M.D., F.A.C.S. is a breast surgeon who directs the newly developed Breast Care Center at Lankenau Hospital in Wynnewood, Pa. Among her many interests, Dr. Sabol spearheads several research initiatives to advance the care for women with breast cancer and improve methods of breast cancer detection and treatment.